Wealth Enhancement Advisory Services LLC Has $49.20 Million Stock Position in Danaher Co. (NYSE:DHR)

Wealth Enhancement Advisory Services LLC boosted its stake in shares of Danaher Co. (NYSE:DHR) by 1.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 196,910 shares of the conglomerate’s stock after purchasing an additional 2,395 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Danaher were worth $49,198,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Cary Street Partners Investment Advisory LLC boosted its stake in Danaher by 20.2% during the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock worth $2,112,000 after buying an additional 1,533 shares in the last quarter. Cercano Management LLC raised its position in Danaher by 11.4% in the fourth quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock worth $46,862,000 after purchasing an additional 20,715 shares in the last quarter. Donaldson Capital Management LLC grew its stake in shares of Danaher by 5.8% in the 1st quarter. Donaldson Capital Management LLC now owns 1,469 shares of the conglomerate’s stock valued at $367,000 after purchasing an additional 80 shares during the period. Caden Capital Partners LP raised its holdings in shares of Danaher by 12.4% in the 4th quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock worth $32,172,000 after buying an additional 15,313 shares in the last quarter. Finally, Legacy Financial Advisors Inc. boosted its stake in Danaher by 2.4% in the 4th quarter. Legacy Financial Advisors Inc. now owns 2,377 shares of the conglomerate’s stock valued at $550,000 after buying an additional 55 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Danaher news, CEO Rainer Blair sold 9,005 shares of the business’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total value of $2,386,325.00. Following the sale, the chief executive officer now directly owns 106,990 shares of the company’s stock, valued at $28,352,350. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Danaher news, CEO Rainer Blair sold 9,005 shares of Danaher stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $265.00, for a total value of $2,386,325.00. Following the completion of the transaction, the chief executive officer now directly owns 106,990 shares of the company’s stock, valued at $28,352,350. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Linda Filler sold 3,928 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the sale, the director now directly owns 41,149 shares of the company’s stock, valued at approximately $11,501,145.50. The disclosure for this sale can be found here. Insiders have sold 47,712 shares of company stock worth $13,173,269 in the last 90 days. Insiders own 11.10% of the company’s stock.

Danaher Price Performance

DHR traded down $1.82 on Wednesday, reaching $266.89. The company had a trading volume of 313,825 shares, compared to its average volume of 2,870,704. The business has a 50 day simple moving average of $257.53 and a 200 day simple moving average of $252.98. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The company has a market cap of $197.68 billion, a price-to-earnings ratio of 45.54, a P/E/G ratio of 4.62 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. Danaher’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same period last year, the business posted $2.05 earnings per share. As a group, sell-side analysts anticipate that Danaher Co. will post 7.59 EPS for the current year.

Analysts Set New Price Targets

DHR has been the subject of a number of research analyst reports. The Goldman Sachs Group lifted their target price on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. HSBC upgraded Danaher from a “hold” rating to a “buy” rating and increased their target price for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. Stifel Nicolaus increased their price objective on shares of Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. TD Cowen boosted their target price on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Finally, StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Six equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $276.88.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.